Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
AstraZeneca aims to harness VaxEquity’s saRNA platform for use with its own therapeutic programs and intends to widely use it on up to 26 different drug targets.
GlaxoSmithKline Chief Executive Officer Emma Walmsley faces renewed calls for her ouster after Bluebell Capital Partners has taken a £10 million (about $13.7 million) stake in the company.
Aurion Biotech is focused on curative and restorative treatments for corneal endothelial disease.
As of September 11, slightly over 100 Alzheimer’s patients had received the drug, reported to be dramatically below Biogen’s internal projections and Wall Street expectations.
The startup’s initial focus will be on rare blindness conditions affecting pediatric patients.
Nektar collaborates with Pfizer and Merck KGaA, Darmstadt, Germany, to assess NKTR-255 in combination with Bavencio in patients with bladder cancer.
On Tuesday, 858 Therapeutics launched with a $60 million Series A financing round under its belt.
MiroBio’s pipeline involves checkpoint receptor pathways, not for immuno-oncology indications, but for the treatment of autoimmune diseases.